Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers

This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: Multimeric-001, 500 mcg; Biological: PBS and TIV 15%; Biological: Adjuvanted PBS; Biological: PBS and TIV 50%

Detailed Description

This is a Phase II multi-center, randomized, two stage, double-blind, placebo-controlled study comprising 200 participants. Eligible subjects will be randomized to receive one of the following administrations (as two single IM injections with an interval of 21 days between each injection Administration A: Prime twice with Adjuvanted Multimeric-001 500 mcg - 64 subjects.

Administration B: PBS (Placebo) twice - 32 subjects. Administration C: Adjuvanted PBS (Placebo)twice - 32 subjects. Participants from administrations A and B will be further immunized with a 15% dose of commercial seasonal trivalent vaccine for 2011 on day 81.

Administration D: Adjuvanted Multimeric-001 500 mcg coadministered once with 15% of TIV dose - 24 subjects. Administration E: Adjuvanted Multimeric-001 500 mcg coadministered once with 50% of TIV dose - 24 subjects Administration group F: PBS (Placebo) co-administered once with 50% of TIV dose - 24 subjects

• Study Type: Interventional
• Enrollment (Actual): 200
• Phase: Phase 2

Contacts and Locations

Study Locations

• Israel
  • Jerusalem, Israel
    • Clinical Research Center, Hadassah Medical Center
  • Tel-Aviv, Israel
    • Clinical Research Center, Tel-Aviv Sourasky Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy males and females between the age of 18 and 49 years (inclusive).
• Subjects who provide written informed consent to participate in the study.
• Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.
• Haematology, chemistry and urinalysis values with no clinical significance or do not reflect a medical condition which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.
• Female of childbearing age must agree to use an acceptable method of contraception and male subjects should use a condom throughout the study period (until termination visit) if female partner is not using an effective contraceptive method.
• Subjects who are seronegative to at least one of the strains included in the seasonal vaccine against influenza for 2011.

Exclusion Criteria:

• Known history of significant medical disorder, which in the investigator's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.
• Subjects with known Guillain Barré Syndrome in the past.
• Two or more hospitalizations within the last year prior to screening visit.
• Known bleeding disorders including hemophilia or thrombocytopenia, or treatment with anticoagulant therapy (risk of bleeding with intramuscular injection).
• Immunocompromised patients and those receiving concomitant immunosuppressive therapy; or other immune modulating drugs including chronic steroid treatment.
• Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within eight months prior to the screening visit.
• Administration of any vaccine 30 days before the screening visit.
• Known hypersensitivity to previous influenza vaccination.
• Use of an influenza antiviral medication within 4 weeks of vaccination.
• Known hypersensitivity and/or allergy to any drug or vaccine.
• Known hypersensitivity to egg proteins (eggs or egg products), chicken proteins, or any of the vaccine components.
• Known history of drug or alcohol abuse.
• Any clinically significant abnormality upon physical examination or in the clinical laboratory tests at screening visit which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study.
• Increased liver enzymes more than 2.5 times above the upper reference level.
• Positive serology for HIV, HCV antibody or HBsAg.
• Any acute medical situation (e.g. acute infection, ongoing flu symptoms) with or without fever within 48 hours of vaccination, which is considered of significance by the Principal Investigator.
• Pregnant or lactating women at entry to study and those who are unwilling to agree to continue to use acceptable methods of contraception for two months after completion of the study (if applicable).
• Positive blood pregnancy test on screening.
• Subjects who participated in any clinical study within 30 days prior to study entry
• Subjects who are non-cooperative or unwilling to sign consent form.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Multimeric-001, Adjuvanted; 64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).	Biological: Multimeric-001, 500 mcg; Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
Active Comparator: PBS and TIV 15%; 32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).	Biological: PBS and TIV 15%; PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
Placebo Comparator: Placebo, Adjuvanted; 32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.	Biological: Adjuvanted PBS; Adjuvanted PBS was administered twice with an interval of 19-23 days.; Other Names: placebo
Experimental: Co-administration M-001 and TIV 15%; 24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.	Biological: Multimeric-001, 500 mcg; Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
Experimental: Co administration of M-001 and TIV 50%; 24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.	Biological: Multimeric-001, 500 mcg; Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
Active Comparator: Co administration of PBS and TIV 50%; 24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.	Biological: PBS and TIV 50%; PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Number of Participants with Adverse Events possible/probably related to the study drug in each group were similar in the experimental and control groups.	From day 0 until day 221
Anti Multimeric-001 antibodies	Direct Elisa assay to test the titer of human antibodies that recognize the Multimeric-001 protein. Humoral immunity was manifested 21 and 60 days post immunization by significantly elevated anti-M-001 IgG levels among subjects administered twice with adjuvanted M-001	21 days after second immunization with M-001

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemagglutination Inhibition (HAI) test for anti influenza antibodies	The serum is tested for its ability to adhere to influenza virus and thus inhibit the Hemagglutination reaction. Adjuvanted M-001 co-administered with partial dose of TIV (Vaxigrip, 50%) was effective in enhancing immunity to influenza-related antigens, as manifested by increased HAI antibody responses toward viruses contained in the TIV as well as toward non-TIV virus strains.	21 days post co administration of M-001 and TIV 50%

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cellular Immunogenicity	Elevated proliferation of lymphocytes following in vitro incubation with M-001. The proliferation was associated with IFN gamma secretion	21 days after co administration of M-001 and TIV 50%

Collaborators and Investigators

• Sponsor: BiondVax Pharmaceuticals ltd.
• Investigators: Principal Investigator: Jacob Atsmon, MD, Clinical Research Center, Tel-Aviv Sourasky Medical Center; Principal Investigator: Yosef Caraco, Phd, Clinical Research Center, Hadassah Medical Center, Jerusalem

Study record dates

Study Major Dates

• Study Start: July 1, 2010
• Primary Completion (Actual): May 1, 2011
• Study Completion (Actual): June 1, 2011

Study Registration Dates

• First Submitted: June 13, 2010
• First Submitted That Met QC Criteria: June 16, 2010
• First Posted (Estimate): June 17, 2010

Study Record Updates

• Last Update Posted (Estimate): July 31, 2012
• Last Update Submitted That Met QC Criteria: July 30, 2012
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Keywords: vaccine; Influenza; boost; HAI; seroconversion; universal; immune response; prime
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: BVX-004